Early predictors of Epstein-Barr virus infection in patients with severe fever with thrombocytopenia syndrome.
Co-infection
Dabie Bandavirus
Epstein-Barr virus
Immunity
Risk factors
Severe fever with thrombocytopenia syndrome
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
07 Aug 2024
07 Aug 2024
Historique:
received:
20
11
2023
accepted:
30
07
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
Epstein-Barr virus (EBV) can be reactivated and proliferated with fatal outcome in immuno-compromised people, but the clinical consequences of EBV infection in patients with severe fever with thrombocytopenia syndrome (SFTS) remain uncertain. In this study, we investigated the infection rate, the influence and the early predictors of EBV infection in SFTS patients. In this retrospective study, SFTS patients who were treated in the First Affiliated Hospital of Nanjing Medical University from May 2011 to August 2021 were enrolled and divided into infected and non-infected groups. We compared the demographic characteristics, clinical manifestations and signs, laboratory tests and prognosis, and explored the risk factors of EBV infection by receiver operating characteristic (ROC) curve and logistic regression. A total of 120 hospitalized SFTS patients with EBV-DNA testing were enrolled in this study. Patients with EBV infection had statistically significant higher mortality rate (32.0% vs. 11.43%, P = 0.005). Compared with the non-infected group, the EBV-infected group had higher levels of C-reactive protein (CRP), creatine-kinase (CK), fasting blood glucose (FBG), blood urea nitrogen (BUN), D-dimer, and CD56 SFTS combined with EBV infection is associated with high morbidity and mortality. It is necessary to strengthen screening for EBV infection and its early predictive markers after admission in SFTS patients.
Sections du résumé
BACKGROUND
BACKGROUND
Epstein-Barr virus (EBV) can be reactivated and proliferated with fatal outcome in immuno-compromised people, but the clinical consequences of EBV infection in patients with severe fever with thrombocytopenia syndrome (SFTS) remain uncertain. In this study, we investigated the infection rate, the influence and the early predictors of EBV infection in SFTS patients.
METHODS
METHODS
In this retrospective study, SFTS patients who were treated in the First Affiliated Hospital of Nanjing Medical University from May 2011 to August 2021 were enrolled and divided into infected and non-infected groups. We compared the demographic characteristics, clinical manifestations and signs, laboratory tests and prognosis, and explored the risk factors of EBV infection by receiver operating characteristic (ROC) curve and logistic regression.
RESULTS
RESULTS
A total of 120 hospitalized SFTS patients with EBV-DNA testing were enrolled in this study. Patients with EBV infection had statistically significant higher mortality rate (32.0% vs. 11.43%, P = 0.005). Compared with the non-infected group, the EBV-infected group had higher levels of C-reactive protein (CRP), creatine-kinase (CK), fasting blood glucose (FBG), blood urea nitrogen (BUN), D-dimer, and CD56
CONCLUSIONS
CONCLUSIONS
SFTS combined with EBV infection is associated with high morbidity and mortality. It is necessary to strengthen screening for EBV infection and its early predictive markers after admission in SFTS patients.
Identifiants
pubmed: 39107822
doi: 10.1186/s12985-024-02452-5
pii: 10.1186/s12985-024-02452-5
doi:
Substances chimiques
Antibodies, Viral
0
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179Subventions
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Organisme : the National Natural Science Foundation of China
ID : No. 81871242
Informations de copyright
© 2024. The Author(s).
Références
Casel MA, Park SJ, Choi YK. Severe fever with thrombocytopenia syndrome virus: emerging novel phlebovirus and their control strategy. Exp Mol Med. 2021;53(5):713–22.
doi: 10.1038/s12276-021-00610-1
pubmed: 33953322
pmcid: 8178303
Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Zhang L, Zhang QF, Popov VL, Li C, Qu J, Li Q, Zhang YP, Hai R, Wu W, Wang Q, Zhan FX, Wang XJ, Kan B, Wang SW, Wan KL, Jing HQ, Lu JX, Yin WW, Zhou H, Guan XH, Liu JF, Bi ZQ, Liu GH, RenJ, Wang H, Zhao Z, Song JD, He JR, Wan T, Zhang JS, Fu XP, Sun LN, Dong XP, Feng ZJ, Yang WZ, Hong T, Zhang Y, Walker DH, Wang Y, Li DX. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364(16):1523–32.
doi: 10.1056/NEJMoa1010095
pubmed: 21410387
pmcid: 3113718
Zhang Y, Miao W, Xu Y, Huang Y. Severe fever with thrombocytopenia syndrome in Hefei: clinical features, risk factors, and Ribavirin therapeutic efficacy. J Med Virol. 2021;93(6):3516–23.
doi: 10.1002/jmv.26544
pubmed: 32965706
Miao D, Liu MJ, Wang YX, Ren X, Lu QB, Zhao GP, Dai K, Li XL, Li H, Zhang XA, Shi WQ, Wang LP, Yang Y, Fang LQ, Liu W. Epidemiology and Ecology of severe fever with Thrombocytopenia Syndrome in China, 2010–2018. Clin Infect Dis. 2021;73(11):e3851–8.
doi: 10.1093/cid/ciaa1561
pubmed: 33068430
Chen Q, Yang D, Zhang Y, Zhu M, Chen N, Yushan Z. Transmission and mortality risk assessment of severe fever with thrombocytopenia syndrome in China: results from 11-years’ study. Infect Dis Poverty. 2022;11(1):93.
doi: 10.1186/s40249-022-01017-4
pubmed: 36058928
pmcid: 9440863
Yokomizo K, Tomozane M, Sano C, Ohta R. Clinical presentation and mortality of severe fever with Thrombocytopenia Syndrome in Japan: a systematic review of Case Reports. Int J Environ Res Public Health. 2022;19(4).
Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, Sato Y, Suzuki T, Nagata N, Hasegawa H, Kawai Y, Uda A, Morikawa S, Shimojima M, Watanabe H, Saijo M. Efficacy of T-705 (Favipiravir) in the treatment of infections with Lethal severe fever with Thrombocytopenia Syndrome Virus. mSphere. 2016;1(1).
Lee MJ, Kim KH, Yi J, Choi SJ, Choe PG, Park WB, Kim NJ, Oh MD. In vitro antiviral activity of Ribavirin against severe fever with thrombocytopenia syndrome virus. Korean J Intern Med. 2017;32(4):731–7.
doi: 10.3904/kjim.2016.109
pubmed: 27899013
Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022;185(20):3652–70.
doi: 10.1016/j.cell.2022.08.026
pubmed: 36113467
pmcid: 9529843
Simonnet A, Engelmann I, Moreau AS, Garcia B, Six S, El Kalioubie A, Robriquet L, Hober D, Jourdain M. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51(3):296–9.
doi: 10.1016/j.idnow.2021.01.005
pubmed: 33495765
pmcid: 7816954
Olmez O, Baba C, Abasiyanik Z, Ozakbas S. Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location. Mult Scler Relat Disord. 2022;68:104149.
doi: 10.1016/j.msard.2022.104149
pubmed: 36096010
Jin K, Dai Y, Ouyang K, Huang H, Jiang Z, Yang Z, Zhou T, Lin H, Wang C, Wang C, Sun X, Lu D, Liu X, Hu N, Zhu C, Zhu J, Li J. TRIM3 attenuates cytokine storm caused by Dabie Bandavirus via promoting toll-like receptor 3 degradation. Front Microbiol. 2023;14:1209870.
doi: 10.3389/fmicb.2023.1209870
pubmed: 37520369
pmcid: 10375709
Khalil J, Yamada S, Tsukamoto Y, Abe H, Shimojima M, Kato H, Fujita T. The nonstructural protein NSs of severe fever with Thrombocytopenia Syndrome Virus causes a cytokine storm through the hyperactivation of NF-κB. Mol Cell Biol. 2021;41(3):e0054220.
doi: 10.1128/MCB.00542-20
pubmed: 33288641
Ministry of Health P. Guideline for prevention and treatment of sever fever with thrombocytopenia syndrome (2010 vesrion). Chin J Clin Infect Dis. 2011;04(4):193–4.
Fei X, Feng B, Fang K, Ren W. Risk factors for mortality in severe fever with Thrombocytopenia Syndrome patients with Central Nervous System complications. Med Sci Monit. 2023;29:e938427.
doi: 10.12659/MSM.938427
pubmed: 36959721
pmcid: 10044005
Wang M, Huang P, Liu W, Tan W, Chen T, Zeng T, Zhu C, Shao J, Xue H, Li J, Yue M. Risk factors of severe fever with thrombocytopenia syndrome combined with central neurological complications: a five-year retrospective case-control study. Front Microbiol. 2022;13:1033946.
doi: 10.3389/fmicb.2022.1033946
pubmed: 36406394
pmcid: 9668900
Yang T, Huang H, Jiang L, Li J. Overview of the immunological mechanism underlying severe fever with thrombocytopenia syndrome (review). Int J Mol Med. 2022;50(3).
Sánchez-Ponce Y, Fuentes-Pananá EM. The role of coinfections in the EBV-Host broken equilibrium. Viruses. 2021;13(7).
Fujimoto K, Hatanaka KC, Hatanaka Y, Kasahara I, Yamamoto S, Tsuji T, Nakata M, Takakuwa Y, Haseyama Y, Oyamada Y, Yonezumi M, Suzuki H, Sakai H, Noguchi H, Mori A, Nishihara H, Teshima T, Matsuno Y. Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseases. Hematol Oncol. 2020;38(5):799–807.
doi: 10.1002/hon.2790
pubmed: 32798315
Naendrup JH, Garcia Borrega J, Eichenauer DA, Shimabukuro-Vornhagen A, Kochanek M, Böll B. Reactivation of EBV and CMV in severe COVID-19-Epiphenomena or trigger of hyperinflammation in need of treatment? A large Case Series of critically ill patients. J Intensive Care Med. 2022;37(9):1152–8.
doi: 10.1177/08850666211053990
pubmed: 34791940
pmcid: 9396115
Zhou JR, Shi DY, Wei R, Wang Y, Yan CH, Zhang XH, Xu LP, Liu KY, Huang XJ, Sun YQ. Co-reactivation of Cytomegalovirus and Epstein-Barr Virus was Associated with Poor Prognosis after allogeneic stem cell transplantation. Front Immunol. 2020;11:620891.
doi: 10.3389/fimmu.2020.620891
pubmed: 33664733
Mendoza CA, Ebihara H, Yamaoka S. Immune Modulation and Immune-mediated pathogenesis of emerging Tickborne Banyangviruses. Vaccines (Basel). 2019;7(4).
Hu L, Kong Q, Yue C, Xu X, Xia L, Bian T, Liu Y, Zhang H, Ma X, Yin H, Sun Q, Gao Y, Ye Y, Li J. Early-warning Immune predictors for Invasive Pulmonary aspergillosis in severe patients with severe fever with Thrombocytopenia Syndrome. Front Immunol. 2021;12:576640.
doi: 10.3389/fimmu.2021.576640
pubmed: 34025635
pmcid: 8138034
Ge HH, Wang G, Guo PJ, Zhao J, Zhang S, Xu YL, Liu YN, Ye XL, Wu YX, Li S, Yue M, Ji WJ, Geng SY, LiH, Zhang XA, Yang ZD, Cui N, Li W, Lin L, Liu W. Coinfections in hospitalized patients with severe fever with thrombocytopenia syndrome: a retrospective study. J Med Virol. 2022;94(12):5933–42.
doi: 10.1002/jmv.28093
pubmed: 36030552
Xia B, Wang X, Yang R, Mengzhen L, Yang K, Ren L, Li S, Wang S, Zhang Y. Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma. Biosci Rep. 2019;39(10).
Hu J, Zhao H, Lou D, Gao H, Yang M, Zhang X, Jia H, Li L. Human cytomegalovirus and Epstein-Barr virus infections, risk factors, and their influence on the liver function of patients with acute-on-chronic liver failure. BMC Infect Dis. 2018;18(1):577.
doi: 10.1186/s12879-018-3488-8
pubmed: 30445927
pmcid: 6240234
Meng M, Zhang S, Dong X, Sun W, Deng Y, Li W, Li R, Annane D, Wu Z, Chen D. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun Inflamm Dis. 2022;10(4):e597.
doi: 10.1002/iid3.597
pubmed: 35349757
pmcid: 8959425
Kang SY, Yoo JR, Park Y, Kim SH, Heo ST, Park SH, Kim M, Kim TJ, Oh S, Lee MS, Kim JM, Cho NH, Lee KM, Lee KH. Fatal outcome of severe fever with thrombocytopenia syndrome (SFTS) and severe and critical COVID-19 is associated with the hyperproduction of IL-10 and IL-6 and the low production of TGF-β. J Med Virol. 2023;95(7):e28894.
doi: 10.1002/jmv.28894
pubmed: 37386895
Gong L, Zhang L, Wu J, Lu S, Lyu Y, Zhu M, Liu B, Zhu Y, Song D, Su B, Liu Z. Clinical progress and risk factors for death from severe fever with Thrombocytopenia Syndrome: a multihospital Retrospective Investigation in Anhui, China. Am J Trop Med Hyg. 2021;104(4):1425–31.
doi: 10.4269/ajtmh.20-0270
pubmed: 33591933
pmcid: 8045620
Xiong L, Xu L, Lv X, Zheng X. Effects of corticosteroid treatment in patients with severe fever with thrombocytopenia syndrome: a single-center retrospective cohort study. Int J Infect Dis. 2022;122:1026–33.
doi: 10.1016/j.ijid.2022.07.001
pubmed: 35803466
Gao H, Wang B, Yao H, Zhang W, Teng H. Application of blood purification technology in severe fever with thrombocytopenia syndrome. Biotechnol Genet Eng Rev. 2023:1–10.
Chen K, Sun H, Geng Y, Yang C, Shan C, Chen Y. Ferritin and procalcitonin serve as discriminative inflammatory biomarkers and can predict the prognosis of severe fever with thrombocytopenia syndrome in its early stages. Front Microbiol. 2023;14:1168381.
doi: 10.3389/fmicb.2023.1168381
pubmed: 37143532
pmcid: 10151901
Xie J, Su M, Dang Y, Zhao L. Prognostic Value of Serum Ferritin for patients with severe fever with Thrombocytopenia Syndrome: a single-Center Retrospective Cohort Study. Infect Dis Ther. 2023;12(3):979–88.
doi: 10.1007/s40121-023-00784-3
pubmed: 36884213
pmcid: 9994411
Sun Y, Huang T, Hammarström L, Zhao Y. The immunoglobulins: New insights, implications, and applications. Annu Rev Anim Biosci. 2020;8:145–69.
doi: 10.1146/annurev-animal-021419-083720
pubmed: 31846352
Labrosse R, Barmettler S, Derfalvi B, Blincoe A, Cros G, Lacombe-Barrios J, Barsalou J, Yang N, Alrumayyan N, Sinclair J, Ong MS, Camargo CA Jr., Walter J, Haddad E. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. J Allergy Clin Immunol. 2021;148(2):523–e532528.
doi: 10.1016/j.jaci.2021.03.041
pubmed: 33862010
Garred P, Tenner AJ, Mollnes TE. Therapeutic targeting of the complement system: from Rare diseases to Pandemics. Pharmacol Rev. 2021;73(2):792–827.
doi: 10.1124/pharmrev.120.000072
pubmed: 33687995
pmcid: 7956994
Lee SY, Yun SH, Lee H, Lee YG, Seo G, Kim NH, Park EC, Lee CS, Kim SI. Serum proteomics of severe fever with thrombocytopenia syndrome patients. Clin Proteom. 2022;19(1):32.
doi: 10.1186/s12014-022-09368-8
Mujal AM, Delconte RB, Sun JC. Natural killer cells: from innate to adaptive features. Annu Rev Immunol. 2021;39:417–47.
doi: 10.1146/annurev-immunol-101819-074948
pubmed: 33902312
Zhao J, Lu QB, Li H, Yuan Y, Cui N, Yuan C, Zhang XA, Yang ZD, Ruan SM, Liu LZ, Du J, Fang LQ, Liu W. Sex differences in Case Fatality rate of patients with severe fever with Thrombocytopenia Syndrome. Front Microbiol. 2021;12:738808.
doi: 10.3389/fmicb.2021.738808
pubmed: 34721338
pmcid: 8552034
Cantan B, Luyt CE, Martin-Loeches I. Influenza Infections and emergent viral infections in Intensive Care Unit. Semin Respir Crit Care Med. 2019;40(4):488–97.
doi: 10.1055/s-0039-1693497
pubmed: 31585475
pmcid: 7117087